Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bezmialem Vakif Üniversitesi has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. Prosecution for this matter is currently handled by 1 distinct examiner, SAIDHA, TEKCHAND. The portfolio involves 1 distinct art unit for its active filings, which indicates a focused approach to its current intellectual property development in the biotech sector.
SAIDHA, TEKCHAND is the busiest examiner for the university, responsible for 1 busiest examiner pending action. Since the total number of pending office actions is 1, this examiner is managing the institution's entire active patent prosecution workload. The alignment of 1 distinct examiner and 1 distinct art unit for the 1 pending office action suggests a singular point of focus for the institution's current patenting efforts. Practitioners can observe that the 1 busiest examiner pending action held by SAIDHA, TEKCHAND represents the full scope of the university's current engagement with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAIDHA, TEKCHAND | 1 | 82.9% | +14.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18845882 | ACE2 HOMOLOGOUS PEPTIDE SEQUENCES | SAIDHA, TEKCHAND | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18845882 | ACE2 HOMOLOGOUS PEPTIDE SEQUENCES | SAIDHA, TEKCHAND | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18845882 | ACE2 HOMOLOGOUS PEPTIDE SEQUENCES | SAIDHA, TEKCHAND | 1652 | §102§112Other | Non-Final OA | — | Pending | Sep 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial